Drug-Eluting Stents: Safe But Not Sufficient

All drug-eluting stents are equal, but some drug-eluting stents are more equal than others.

b t r t a s S g S d s b r a p a T v v p he first battle fought by drug-eluting stents (DES) was ith bare-metal stents. The 2 DES approved by the U.S. ood and Drug Administration, sirolimus drug-eluting tents (S-DES) and paclitaxel drug-eluting stents (P-DES), howed superiority in significantly reducing restenosis rates nd target lesion revascularization rates compared with are-metal stents in a...

Drug-eluting stents.

New Drug-Eluting Stents

The introduction of drug-eluting stents (DES) has rapidly and profoundly affected the field of interventional cardiology, and DESs are now used in a majority of intracoronary stenting procedures. As a result of the innumerable “trial-and-error” endeavors, DESs have emerged as a potential solution for solving the problem of restenosis. DESs are coated stents capable of releasing single or multip...

Drug-Eluting Stents

n the history of percutaneous coronary intervention, drug-eluting stents (DES) are recognized as revolutionary technologies with their unique ability to provide both mechanical and biological solutions simultaneously to the target lesion. While the clinical success of DES depends on these 2 properties, the ability of the operator to properly deploy the device is also of utmost importance. Altho...

Drug-eluting/biodegradable stents.